Cogent Biosciences Inc (COGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has a cash flow conversion efficiency ratio of -0.124x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-79.11 Million) by net assets ($636.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View COGT stock price and chart for real-time trading data and today's change.
Cogent Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of Cogent Biosciences Inc for the company's overall valuation and market capitalisation.
Cogent Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cogent Biosciences Inc ranked by their cash flow conversion efficiency. Also see Cogent Biosciences Inc balance sheet assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compagnie du Cambodge
PA:CBDG
|
0.004x |
|
Fortnox AB
ST:FNOX
|
0.058x |
|
Perseus Mining Ltd
TO:PRU
|
0.078x |
|
Hangzhou First PV Material Co Ltd
SHG:603806
|
0.057x |
|
Inner Mongolia Dazhong Mining Co Ltd
SHE:001203
|
0.060x |
|
Carlsberg A/S
CO:CARL-A
|
0.241x |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
-0.027x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Cogent Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Cogent Biosciences Inc from 2015 to 2025. Review Cogent Biosciences Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $636.37 Million | $-264.44 Million | -0.416x | +48.75% |
| 2024-12-31 | $256.29 Million | $-207.79 Million | -0.811x | -36.06% |
| 2023-12-31 | $257.80 Million | $-153.62 Million | -0.596x | -28.45% |
| 2022-12-31 | $255.74 Million | $-118.64 Million | -0.464x | -69.09% |
| 2021-12-31 | $214.18 Million | $-58.76 Million | -0.274x | -79.59% |
| 2020-12-31 | $234.67 Million | $-35.85 Million | -0.153x | +88.31% |
| 2019-12-31 | $31.76 Million | $-41.51 Million | -1.307x | -142.32% |
| 2018-12-31 | $60.23 Million | $-32.49 Million | -0.539x | +40.91% |
| 2017-12-31 | $28.30 Million | $-25.84 Million | -0.913x | -156.53% |
| 2016-12-31 | $52.39 Million | $-18.64 Million | -0.356x | -239.62% |
| 2015-12-31 | $69.52 Million | $17.72 Million | 0.255x | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more